IL143353A0 - Expression system for factor viii - Google Patents

Expression system for factor viii

Info

Publication number
IL143353A0
IL143353A0 IL14335399A IL14335399A IL143353A0 IL 143353 A0 IL143353 A0 IL 143353A0 IL 14335399 A IL14335399 A IL 14335399A IL 14335399 A IL14335399 A IL 14335399A IL 143353 A0 IL143353 A0 IL 143353A0
Authority
IL
Israel
Prior art keywords
factor viii
expression system
glycosylated
linked
oligosaccharides
Prior art date
Application number
IL14335399A
Other languages
English (en)
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of IL143353A0 publication Critical patent/IL143353A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
IL14335399A 1998-12-10 1999-12-08 Expression system for factor viii IL143353A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/209,916 US6358703B1 (en) 1998-12-10 1998-12-10 Expression system for factor VIII
PCT/US1999/029169 WO2000034505A1 (en) 1998-12-10 1999-12-08 Expression system for factor viii

Publications (1)

Publication Number Publication Date
IL143353A0 true IL143353A0 (en) 2002-04-21

Family

ID=22780858

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14335399A IL143353A0 (en) 1998-12-10 1999-12-08 Expression system for factor viii
IL143353A IL143353A (en) 1998-12-10 2001-05-24 Method for producing and isolating a protein having factor viii activity and a cell line

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL143353A IL143353A (en) 1998-12-10 2001-05-24 Method for producing and isolating a protein having factor viii activity and a cell line

Country Status (26)

Country Link
US (10) US6358703B1 (pt)
EP (1) EP1137797B1 (pt)
JP (1) JP4240818B2 (pt)
KR (1) KR100616028B1 (pt)
AT (1) ATE412765T1 (pt)
AU (1) AU761801B2 (pt)
BG (1) BG65431B1 (pt)
BR (1) BRPI9916069B8 (pt)
CA (1) CA2354845C (pt)
CZ (1) CZ302330B6 (pt)
DE (1) DE69939839D1 (pt)
DK (1) DK1137797T3 (pt)
ES (1) ES2315026T3 (pt)
HU (1) HU228489B1 (pt)
IL (2) IL143353A0 (pt)
NO (1) NO329544B1 (pt)
NZ (1) NZ512234A (pt)
PL (1) PL200676B1 (pt)
PT (1) PT1137797E (pt)
RO (1) RO121604B1 (pt)
RU (1) RU2249041C2 (pt)
SI (1) SI20644B (pt)
SK (1) SK286945B6 (pt)
TR (1) TR200101592T2 (pt)
UA (1) UA77383C2 (pt)
WO (1) WO2000034505A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6180108B1 (en) * 1998-12-10 2001-01-30 Bayer Corporation Vectors having terminal repeat sequence of Epstein-Barr virus
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
AU5471501A (en) * 2000-03-22 2001-10-03 Octagene Gmbh Production of recombinant blood clotting factors in human cell lines
DE60234193D1 (de) * 2001-06-14 2009-12-10 Scripps Research Inst Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen
PT1596887T (pt) 2003-02-26 2022-04-14 Nektar Therapeutics Conjugados polímero-porção fator viii
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
US7498024B2 (en) * 2003-06-03 2009-03-03 Cell Genesys, Inc. Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site
WO2006050050A2 (en) * 2004-10-29 2006-05-11 Centocor, Inc. Chemically defined media compositions
HUE050542T2 (hu) * 2004-11-12 2020-12-28 Bayer Healthcare Llc FVIII helyspecifikus módosítása
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
PL2253644T3 (pl) 2005-12-20 2014-04-30 Bristol Myers Squibb Co Kompozycje i sposoby wytwarzania kompozycji
SI2574677T1 (sl) 2007-12-27 2017-11-30 Baxalta GmbH Procesi celične kulture
KR101005967B1 (ko) * 2008-04-12 2011-01-05 (주)셀트리온 우수한 재조합 단백질을 생산하기 위한 인간 숙주 세포
CA2728708A1 (en) * 2008-06-25 2009-12-30 Bayer Healthcare Llc Factor viii muteins with reduced immunogenicity
MX2011001624A (es) 2008-08-21 2011-03-28 Octapharma Ag Factor viii y ix humano producido en forma recombinante.
KR20110073434A (ko) * 2008-09-03 2011-06-29 옥타파마 아게 재조합에 의해 제조된 인자 ⅷ을 위한 신규한 보호 조성물
EP2393828B1 (en) 2009-02-03 2016-10-12 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
EP2411024A4 (en) * 2009-03-24 2013-02-27 Bayer Healthcare Llc Variants of factor viii and associated methods of use
JP5813641B2 (ja) 2009-08-24 2015-11-17 アムニクス オペレーティング インコーポレイテッド 凝固第ｉｘ因子組成物ならびにそれを製造および使用する方法
US20110150843A1 (en) * 2009-10-30 2011-06-23 National Institute Of Immunology Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells
US20130017997A1 (en) * 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
WO2012156356A1 (en) * 2011-05-13 2012-11-22 Octapharma Ag A method of increasing the productivity of eucaryotic cells in the production of recombinant fviii
MY201293A (en) 2012-01-12 2024-02-15 Bioverativ Therapeutics Inc Chimeric factor viii polypeptides and uses thereof
CA2864904C (en) 2012-02-15 2023-04-25 Amunix Operating Inc. Factor viii compositions and methods of making and using same
AU2013204636B2 (en) 2012-02-15 2016-04-14 Bioverativ Therapeutics Inc. Recombinant Factor VIII proteins
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
PT4176894T (pt) 2014-01-10 2024-05-21 Bioverativ Therapeutics Inc Proteínas quiméricas de fator viii e utilizações destas
EP3331608A4 (en) 2015-08-03 2019-05-01 Bioverativ Therapeutics Inc. FUSION XI FUSION PROTEINS AND METHODS OF MAKING AND USING THE SAME
CA3020346A1 (en) 2016-04-15 2017-10-19 Baxalta Incorporated Method and apparatus for providing a pharmacokinetic drug dosing regimen
CN109475639A (zh) 2016-07-22 2019-03-15 尼克塔治疗公司 具有含肟键联的因子viii部分的轭合物
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
WO2019055717A1 (en) * 2017-09-13 2019-03-21 Evolve Biosystems, Inc. OLIGOSACCHARIDE COMPOSITIONS AND THEIR USE DURING THE TRANSIENT PHASES OF INTESTINAL MICROBIOMA OF A MAMMALIAN
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
US12030925B2 (en) 2018-05-18 2024-07-09 Bioverativ Therapeutics Inc. Methods of treating hemophilia A
WO2020086686A2 (en) * 2018-10-23 2020-04-30 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045849B2 (ja) 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
KR890002004B1 (ko) * 1984-01-11 1989-06-07 가부시끼 가이샤 도오시바 지폐류 판별장치
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
CA1341174C (en) * 1985-04-12 2001-01-30 John J. Toole Jr. Procoagulant proteins derived from factor viii: c
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
ATE63335T1 (de) * 1986-07-11 1991-05-15 Miles Inc Herstellung von rekombinantem protein.
DK175363B1 (da) 1986-09-12 2004-09-13 Genentech Inc Fremgangsmåde til kontinuert produktion af et önsket heterologt protein i en eukaryotisk værtcelle, vektor, som tilförer denne evne, og celler transformeret med vektoren
IL86693A (en) * 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins that have the activity IIIV of the blood, a process for their preparation that uses cells are produced through genetic engineering and pharmaceutical preparations that contain them
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5661008A (en) * 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
EP0874057B1 (en) * 1993-06-10 2004-07-28 Bayer Corporation Vector and mammalian cell line having improved productivity
US5952198A (en) * 1995-05-04 1999-09-14 Bayer Corporation Production of recombinant Factor VIII in the presence of liposome-like substances of mixed composition
DE19517194A1 (de) * 1995-05-11 1996-11-14 Giesecke & Devrient Gmbh Vorrichtung und Verfahren zur Prüfung von Blattgut, wie z.B. Banknoten oder Wertpapiere
MX9504215A (es) 1995-10-05 1997-04-30 Inst Politecnico Nacional Procedimiento mejorado para la purificacion de oligopeptidos con pesos moleculares de 1000 a 10,000 daltones, a partir de estractos leucocitos y su presentacion farmaceutica.
US5922959A (en) * 1996-10-15 1999-07-13 Currency Systems International Methods of measuring currency limpness
US5923413A (en) * 1996-11-15 1999-07-13 Interbold Universal bank note denominator and validator
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
EP1036177A1 (en) * 1997-12-05 2000-09-20 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
US6040584A (en) * 1998-05-22 2000-03-21 Mti Corporation Method and for system for detecting damaged bills
US6528286B1 (en) * 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6136599A (en) * 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
US6180108B1 (en) * 1998-12-10 2001-01-30 Bayer Corporation Vectors having terminal repeat sequence of Epstein-Barr virus

Also Published As

Publication number Publication date
US20090036358A1 (en) 2009-02-05
EP1137797B1 (en) 2008-10-29
AU2170100A (en) 2000-06-26
US8207117B2 (en) 2012-06-26
BR9916069A (pt) 2001-09-04
UA77383C2 (uk) 2006-12-15
EP1137797A4 (en) 2005-06-22
US7459525B2 (en) 2008-12-02
JP2002531137A (ja) 2002-09-24
SK286945B6 (sk) 2009-08-06
HU228489B1 (en) 2013-03-28
KR20020013481A (ko) 2002-02-20
PT1137797E (pt) 2008-12-26
BG105567A (en) 2002-03-29
RU2249041C2 (ru) 2005-03-27
KR100616028B1 (ko) 2006-08-28
EP1137797A1 (en) 2001-10-04
US8945869B2 (en) 2015-02-03
NO20012718D0 (no) 2001-06-01
IL143353A (en) 2010-12-30
TR200101592T2 (tr) 2001-11-21
US20020102730A1 (en) 2002-08-01
US20030077752A1 (en) 2003-04-24
BG65431B1 (bg) 2008-07-31
SI20644B (sl) 2009-04-30
CA2354845C (en) 2008-08-12
NZ512234A (en) 2002-12-20
RO121604B1 (ro) 2007-12-28
US9650431B2 (en) 2017-05-16
ATE412765T1 (de) 2008-11-15
US20020115152A1 (en) 2002-08-22
PL349284A1 (en) 2002-07-15
CZ302330B6 (cs) 2011-03-16
US6358703B1 (en) 2002-03-19
NO329544B1 (no) 2010-11-08
US20110144025A1 (en) 2011-06-16
DK1137797T3 (da) 2009-02-23
HUP0200558A2 (en) 2002-06-28
US20170267745A1 (en) 2017-09-21
US9249209B2 (en) 2016-02-02
CZ20012024A3 (cs) 2001-10-17
US20130267468A1 (en) 2013-10-10
PL200676B1 (pl) 2009-01-30
US20160115219A1 (en) 2016-04-28
BRPI9916069B1 (pt) 2016-08-02
SI20644A (sl) 2002-02-28
CA2354845A1 (en) 2000-06-15
BRPI9916069B8 (pt) 2021-05-25
ES2315026T3 (es) 2009-03-16
JP4240818B2 (ja) 2009-03-18
HUP0200558A3 (en) 2004-11-29
US20130143818A1 (en) 2013-06-06
SK7922001A3 (en) 2002-01-07
WO2000034505A1 (en) 2000-06-15
NO20012718L (no) 2001-06-01
AU761801B2 (en) 2003-06-12
DE69939839D1 (de) 2008-12-11

Similar Documents

Publication Publication Date Title
IL143353A0 (en) Expression system for factor viii
BG104149A (en) Interleukin-18-binding proteins, methods for their preparation and administration
IT1284373B1 (it) Disposizione di fissaggio di guarniture in particolare minuteria per mobili.
HUP9900323A2 (hu) Bakteriofág endoszialidáz aktivitással rendelkező rekombináns fehérje
AU3510200A (en) Human dickkopf-related protein and nucleic acid molecules and uses therefor
AU7556991A (en) Recombinant beta -1,4 glucan synthase proteins
TR199600116A2 (tr) Bir delta-5,7 sterol, delta-7 reduktaz aktivitesi, delta 7-red proteinine sahip bir a. talian proteini icin dna sirasi kodlamasi, üretim islemi, dönüstürülmüs maya türü, kullanimlari.
WO2001012660A3 (en) HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
EP0644884A4 (en) NOVEL TETRAHYDROCANNABINOL DERIVATIVES, CONJUGATES AND TRACERS OF TETRAHYDROCANNABINOL DERIVATIVES FIXED TO PROTEINS AND POLYPEPTIDES.
AU6142899A (en) Human transferase proteins
EP0749312A4 (en) DIROFILARIA IMMITIS - Gp29 - PROTEINS, NUCLEIC ACID MOLECULES AND THEIR USE
ES8700051A1 (es) Un procedimiento para preparar una composicion oral estable,formadora de espuma
AU1507499A (en) Human nap1 protein
ZA200007633B (en) Pesticide preparations in the form of aqueous suspension.
AU2486900A (en) Rubredoxin fusion proteins, protein expression system and methods
AU4974299A (en) Methods and constructs for protein expression
AU2071799A (en) Placental protein 13
EP1071749A4 (en) NUCLEIC ACID AND LRSG PROTEIN MOLECULES AND USES THEREOF
MX250271B (es) Expresion de proteinas en hongos geneticamente modificados.
GB2349150B (en) Expression of DNA or proteins in C. Elegans
NZ303133A (en) glycosylated human beta interferon
WO2001004297A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
AU5649299A (en) Protein solution preparation and method for stabilizing the same
AU5730300A (en) Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto
AU4221597A (en) Plant-origin regulator protein and nucleic acid encoding the same